Eugia Pharma Launches Generic Pomalidomide Capsules in US Oncology Market

Eugia Pharma Specialities, a subsidiary of Aurobindo Pharma, has launched generic Pomalidomide Capsules in the US market in four dosages (1 mg to 4 mg). The drug, used to treat relapsed or refractory multiple myeloma and AIDS-related Kaposi sarcoma, is a generic equivalent of BMS Pharmaceuticals' Pomalyst. The launch targets a US market estimated at $3.3 billion for the year ending January 2026 and reflects Aurobindo's expansion in oncology and specialty pharmaceuticals.